Pre-Clinical Evaluation Core

临床前评估核心

• 批准号: 10579204
• 负责人: MANDI J. LOPEZ
• 金额: $ 33.64万
• 依托单位: LOUISIANA STATE UNIV A&M COL BATON ROUGE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-01 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10579204
• 关键词: 3-Dimensional; 3D Print; Address; Animal Cancer Model; Animal Diseases; Animal Model; Antineoplastic Agents; Apoptosis; Biological; Biological Assay; Biology; CRISPR/Cas technology; Cancer Model; Cell Culture System; Cell Culture Techniques; Cell Proliferation; Cell Separation; Cells; Centers of Research Excellence; Chronic; Complement; Consult; Consultations; Core Facility; Data Analyses; Development; Disease; Drug Kinetics; Drug Screening; Emerging Technologies; Equipment; Evaluation; Exhibits; Experimental Designs; Extracellular Matrix; Faculty; Gene Expression; Goals; Human; Human Cell Line; Image; Immunohistochemistry; Immunologics; In Vitro; Lung; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of prostate; Measures; Modeling; Molecular Biology; Mus; Mutagenesis; Outcome; Pathology; Patient-Focused Outcomes; Patients; Pharmacotherapy; Population; Postdoctoral Fellow; Pre-Clinical Model; Progressive Disease; Reagent; Regenerative Medicine; Research; Research Personnel; Resource Development; Resources; Services; Signal Pathway; Structure; System; Technology; Therapeutic; Toxic effect; Toxicology; Training; Training and Education; Translational Research; Update; Validation; anticancer research; bioprinting; cancer cell; clinically relevant; experience; genetic manipulation; graduate student; human disease; human model; in vivo; in vivo Model; insight; instrumentation; malignant breast neoplasm; mouse model; novel therapeutic intervention; novel therapeutics; osteosarcoma; pre-clinical; preclinical evaluation; scaffold; screening; three dimensional cell culture; translational cancer research; translational therapeutics; tumor; tumor microenvironment; tumorigenesis

Summary Pre-Clinical Evaluation Core. The Center for Pre-Clinical Cancer Research (Cancer COBRE) aims to identify clinically relevant mechanisms of human cancer using models that closely reflect the disease state in the context of the tumor microenvironment to reveal insights into tumorigenesis and thus drive novel therapeutic discovery. Promising Junior Investigators (PJIs) address devastating and/or chronic human diseases that exhibit poor outcomes in patients and for which there are unmet therapeutic needs. The four PJI projects feature osteosarcoma, breast cancer, liver cancer, and prostate cancer as diseases that would benefit from pre-clinical models that are more predictive of mechanistic efficacy in humans. The PJI projects will use specialized in vivo mouse models and/or in vitro 3D tumor spheroids to identify or validate relevant mechanisms of tumorigenesis or for evaluation of novel therapeutic strategies. The Center will promote a unified and coordinated approach by establishing a new specialized core facility, Pre-Clinical Evaluation Core (PCEC), to provide scientific expertise and technical support for the pre-clinical evaluation of the PJI projects. Human and animal diseases are a major focus at the LSU SVM and on the LSU campus. The unique PCEC will provide a centralized approach that will support exploratory, as well as translational assessment of cancer disease mechanisms and therapeutic strategies in humans. To accomplish this approach, advanced 3D cancer cell culture systems (spheroids) will provide critical translational information. The Center has three Aims: Aim 1. To centralize management and coordination of pre-clinical evaluation of tumorigenesis diseases mechanisms and translational therapeutic approaches. Aim 2. To provide the COBRE PJIs and other biomedical investigators with resources for development and analysis of advanced preclinical cancer models, including 3D bioprinting and cell culture training, instrumentation, technical support, and consultation. Aim 3. To educate faculty, staff, postdoctoral fellows, and graduate students regarding pre-clinical evaluation using state-of-the-art in vitro 3D cell cultures to complement in vivo models.

临床前评价核心总结。 临床前癌症研究中心（癌症COBRE）旨在临床上识别 人类癌症的相关机制，使用密切反映疾病状态的模型， 肿瘤微环境的背景，以揭示对肿瘤发生的见解，从而推动新的 治疗发现有前途的初级调查员（PJIs）解决破坏性和/或 在患者中表现出不良结果的慢性人类疾病， 治疗需求。这四个PJI项目的特点是骨肉瘤，乳腺癌，肝癌， 前列腺癌作为疾病，将受益于临床前模型， 对人体的机械功效。PJI项目将使用专门的体内小鼠模型 和/或体外3D肿瘤球体，以鉴定或验证肿瘤发生的相关机制 或用于评估新的治疗策略。该中心将促进统一和协调 通过建立一个新的专业核心设施，临床前评价核心（PCEC）， 为PJI的临床前评价提供科学专业知识和技术支持 项目人类和动物疾病是LSU SVM和LSU校园的主要焦点。 独特的PCEC将提供一种集中的方法，支持探索性，以及 在人类中的癌症疾病机制和治疗策略的翻译评估。 为了实现这种方法，先进的3D癌细胞培养系统（球体）将提供 关键的翻译信息。该中心有三个目标：目标1。集中管理 和协调肿瘤发生疾病机制的临床前评估， 转化治疗方法。目标2.提供COBRE PJIs和其他生物医学 研究人员拥有开发和分析晚期临床前癌症模型的资源， 包括3D生物打印和细胞培养培训，仪器，技术支持， 协商目标3.教育教职员工、博士后研究员和研究生 关于使用最先进的体外3D细胞培养物进行临床前评价， 体内模型